NCT02340104已完成1 期
An Absolute Bioavailability Study of Baricitinib in Healthy Subjects Using the Intravenous Tracer Method
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Baricitinib Following Both the Oral and the IV Dose
研究概览
简要总结
The purpose of this study is to compare how much baricitinib (study drug) gets into the blood stream when it is given as a single dose (in tablet form) and as an intravenous infusion (injection given directly into a vein via a small needle). Each participant in the study will make four visits to the investigator site over the course of about 6 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Are overtly healthy males or females, as determined by medical history and physical examination
- •Male participants: agree to use 2 reliable methods of birth control with female partners of childbearing potential during the study and for at least 3 months following the last dose of study drug
- •Female participants: women not of childbearing potential due to surgical sterilization (at least 3 months after surgical hysterectomy, bilateral oophorectomy with or without hysterectomy, or bilateral tubal occlusion/ligation) confirmed by medical history, or menopause. Menopausal women are women with spontaneous amenorrhea for at least 12 months, not induced by a medical condition such as anorexia nervosa and not taking medications during the amenorrhea that induced the amenorrhea (eg, oral contraceptives, hormones, gonadotropin releasing hormone, anti estrogens, selective estrogen receptor modulators, or chemotherapy). Menopausal status should be confirmed by a follicle stimulating hormone (FSH) level greater than 40 international units per liter (IU/L) at screening. Female participants who have been sterilized by tubal ligation will be required to use contraception from the time of screening until 28 days after the last dose of study drug
- •Have a body mass index of 18.0 to 32.0 kilogram per meter square (kg/m^2), inclusive, at screening
- •Have venous access sufficient to allow for blood sampling and (IV) administration of study drug
排除标准
- •Are participants who have previously completed or withdrawn from this study or any other study investigating baricitinib, and have previously received baricitinib
- •Have known allergies to baricitinib, related compounds, or any components of the formulation, or history of significant atopy
- •Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
- •Have a history or presence of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
- •Have a current or recent history (<30 days prior to screening and/or <45 days prior to day before study drug administration) of a clinically significant bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or mycobacterial infection
- •Have had symptomatic herpes zoster or herpes simplex infection within 90 days prior to dosing
- •Have an absolute neutrophil count (ANC) less than 2 × 109/liter (L) (2000 cells per microliter [cells/μL]) at screening or day before study drug administration. For abnormal values, a single repeat will be allowed
- •Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
- •Show evidence of hepatitis C infection and/or positive hepatitis C antibody
- •Show evidence of hepatitis B infection and/or positive hepatitis B surface antigen
- •Are women who are pregnant or lactating
- •Have been exposed to a live vaccine within 12 weeks prior to the first dose or expected to need/receive a live vaccine (including herpes zoster vaccination) during the course of the study
- •Intend to use over-the-counter or prescription medication and/or herbal supplements within 14 days prior to dosing and during the study (with the exception of occasional paracetamol, which will be permitted at the discretion of the investigator), or intended use of vitamin supplements from study drug administration until discharge from the Clinical Research Unit (CRU)
研究组 & 干预措施
Baricitinib
Experimental
Single oral dose of baricitinib and single intravenous (IV) infusion of [^13C4D3^15N]-baricitinib over 1.5 hours.
干预措施: Baricitinib (Drug)
Baricitinib
Experimental
Single oral dose of baricitinib and single intravenous (IV) infusion of [^13C4D3^15N]-baricitinib over 1.5 hours.
干预措施: [^13C4D3^15N]-baricitinib (Drug)
结局指标
主要结局
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Baricitinib Following Both the Oral and the IV Dose
时间窗: Predose, 0.5, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 Hours Postdose
AUC\[0-∞\] is is the area under the concentration verses time curve from zero to infinity, reported as nanograms times hour per milliliter (ng\*h/mL).
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Pharmacokinetic Study of Baricitinib in Participants With Liver DiseaseLiver DiseasesHepatic InsufficiencyNCT01870388Eli Lilly and Company16
未知
1 期
Relative Bioavailability of the Baricitinib (LY3009104) Commercial Tablet Compared to the Phase 2 Tablets and the Effect of Food on the Bioavailability of the Commercial Tablet in Healthy Japanese SubjectsHealthy VolunteersJPRN-jRCT2080222636Eli Lilly Japan K.K.
已完成
1 期
A Study of LY2835219 in Healthy ParticipantsHealthy VolunteersNCT02327143Eli Lilly and Company11
已完成
1 期
A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult ParticipantsHealthy VolunteersNCT04898101Acerta Pharma BV14
已完成
1 期
A Study of Baricitinib in Healthy Japanese ParticipantsHealthy ParticipantsNCT02263911Eli Lilly and Company16